Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis

Brunner, Andreas; Hinterholzer, Susanne; Riss, P.; Heinze, Georg; Brustmann, Hermann

doi:10.1016/j.ygyno.2011.09.012

Cited by 85 publications

(77 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Expression of B7-H3 on tumor cells and the endothelium of tumor-associated vasculature has been described in ovarian, endometrial, and cervical carcinomas and correlated with higher grade and poor prognosis (217–219). Interestingly, in cervical carcinomas, endothelial B7-H3 expression inversely correlated with CD8 + T cell infiltration (219), whereas there was no correlation in endometrial carcinomas (218). Expression of B7-H3 and B7-H4 has also been demonstrated on tumor vasculature in renal cell carcinomas and is associated with poor prognosis (220, 221).…”

Section: Role Of Blood Vascular Endothelial Cells In Immune Suppressimentioning

confidence: 99%

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

et al. 2016

View full text Add to dashboard Cite

Recently developed cancer immunotherapy approaches including immune checkpoint inhibitors and chimeric antigen receptor T cell transfer are showing promising results both in trials and in clinical practice. These approaches reflect increasing recognition of the crucial role of the tumor microenvironment in cancer development and progression. Cancer cells do not act alone, but develop a complex relationship with the environment in which they reside. The host immune response to tumors is critical to the success of immunotherapy; however, the determinants of this response are incompletely understood. The immune cell infiltrate in tumors varies widely in density, composition, and clinical significance. The tumor vasculature is a key component of the microenvironment that can influence tumor behavior and treatment response and can be targeted through the use of antiangiogenic drugs. Blood vascular and lymphatic endothelial cells have important roles in the trafficking of immune cells, controlling the microenvironment, and modulating the immune response. Improving access to the tumor through vascular alteration with antiangiogenic drugs may prove an effective combinatorial strategy with immunotherapy approaches and might be applicable to many tumor types. In this review, we briefly discuss the host’s immune response to cancer and the treatment strategies utilizing this response, before focusing on the pathological features of tumor blood and lymphatic vessels and the contribution these might make to tumor immune evasion.

show abstract

Section: Role Of Blood Vascular Endothelial Cells In Immune Suppressimentioning

confidence: 99%

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…B7-H3 was first identified in 2001, is an immune-regulatory protein in B7 family of T cell co-stimulatory molecules, which may be a new prognostic marker 7,8. 2IgB7-H3 and 4IgB7-H3 are two isoforms in human beings 9. B7-H3, as a very important co-stimulatory molecule, promotes T-cells proliferation and induces T-cell receptor signaling interferon production 10.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis

Fan¹,

Zhu²,

Yao³

2016

Pak J Med Sci

View full text Add to dashboard Cite

Objective:The co-stimulatory molecule B7-H3 plays an important role in prognosis of several malignancies. However, its prognostic value in clinic in patient with colorectal cancer (CRC) is still controversial. This meta-analysis evaluated the relationship between B7-H3 expression and the outcomes of CRC patients.Methods:PubMed, Google Scholar, Embase, CNKI and Wanfang database were searched for the studies on the relationship between the expression of B7-H3 and prognosis of CRC patients. Pooled odds ratios (ORs) analysis with 95% confidence interval (95% CIs) for lymph node metastasis, 24-month overall survival and 72-month overall survival were performed mainly using Review Manager 5.0.Results:Six articles including 1,202 total CRC cases were included for the meta-analysis. Pooled analysis with fixed-effects model showed that B7-H3 expression had no relationship with lymphatic metastasis in CRC patients (Fixed-effects, OR= 1.18; 95 % CI:0.87–1.61, P=0.28). However, B7-H3 expression was associated with 24-month overall survival (Fixed-effects, OR=0.48, 95% CI:0.32–0.74, P<0.001) and 72-month overall survival (Fixed-effects, OR = 0.61, 95% CI: 0.43–0.85, P< 0.01) in CRC patients.Conclusion:The co-stimulatory molecule B7-H3 expression is negatively associated with lymph node metastasis in CRC. However, B7-H3 detection might be a feasible and effective means to predict the prognosis in CRC patients.

show abstract

“…The physiological and pathological role of B7-H3 remains contentious, with stimulatory (4,15,16) and inhibitory (17)(18)(19) immunoregulatory functions in cellular and antitumor immune response described in early studies. Currently, the non-immunological functions of B7-H3 in cancer progression and chemoresistance have received increasing attention.…”

Section: Introductionmentioning

confidence: 99%

B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity

Zhang

Wang

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. B7-H3 (CD276), known as a member of B7 immunoregulatory family, is a type I transmembrane glycoprotein aberrantly expressed in numerous types of cancer and associated with poor prognosis. However, the role of B7-H3 in oncogenesis and chemosensitivity of mantle cell lymphoma (MCL) remains unknown. We determined the effects of downregulating B7-H3 expression on tumor progression and the sensitivity of chemotherapeutic drug in mantle cell lymphoma. B7-H3 knockdown was performed using lentivirus transduction in the Maver and Z138 mantle cell lymphoma cell lines, respectively. The effects of B7-H3 on cell proliferation, cycle, migration and invasion were investigated by CCK-8 assay, methyl cellulose colony forming assay, PI staining, and Transwell assays in vitro. By establishing Maver and Z138 xenograft models, the effects of B7-H3 on tumorigenicity were observed, and Ki-67 and PCNA was detected by immunohistochemistry. The downregulation of B7-H3 significantly decreased tumor proliferation in MCL in vitro and in vivo. In the B7-H3 knockdown groups of Maver and Z138 xenograft models, the mean inhibition rate of tumor growth was 59.1 and 65.0% (p=0.010 and 0.003), and the expression of both Ki-67 and PCNA were significantly lower, respectively. After B7-H3 silencing, the cell cycles of Maver and Z138 were both arrested at G0/G1 phase, and the cell migration rates and invasion capacity were decreased as well. Moreover, the impacts of B7-H3 RNAi on the antitumor effect of chemotherapy drugs were determined with CCK-8 and Annexin V-FITC/PI assays in vitro and with xenograft models in vivo. The silencing of B7-H3 increased the sensitivity of Maver and Z138 cells to rituximab and bendamustine and enhanced the drug-induced apoptosis, respectively. Our study demonstrates for the first time that B7-H3 promotes mantle cell lymphoma progression and B7-H3 knockdown significantly enhances the chemosensitivity. This may provide a new therapeutic approach to mantle cell lymphoma. IntroductionMantle cell lymphoma (MCL), a heterogeneous subtype of B-cell non-Hodgkin lymphoma (NHL), accounts for ~7% of NHL cases in the USA and Europe and has one of the worst outcomes of all the lymphomas (1,2). It is characterized by the t(11;14) (q13;q32) translocation, which results in overexpression of cyclin D1 and deregulation of the cell cycle (2). At initial diagnosis, most patients with the median age ~68-70 years have advanced stage disease, and the median overall survival is 3-5 years (3). Although several novel agents have proven to be effective, MCL remains a largely incurable disease and the following relapse is still challenging. Therefore, understanding the molecular mechanisms of MCL pathogenesis and drug resistance will aid in the development of highly active targeted therapies for the disease.B7-H3, a new member of B7 immunoregulatory family with immunoglobulin-like structure (4), is induced in activated dendritic cells, monocytes and T cells (5). Aberrant expression of B7-H3 has been reported and associated with poor prog...

show abstract

Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis

Cited by 85 publications

References 36 publications

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

Prognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis

B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity

Contact Info

Product

Resources

About